-
until 2024 as the
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA), is an
agency of the
European Union headquartered in Lisbon, Portugal,...
-
found being sold as a
designer drug in the UK in 2010, and
reported to the
EMCDDA new drug
monitoring service. It was
described by
Alexander Shulgin as similar...
-
According to the
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA) it has been
detected in 25
European countries with the
majority of drug...
- 6
February 2020.
Retrieved 6
February 2020. "
EMCDDA:Drug
policy profiles, Portugal, June 2011".
Emcdda.europa.eu. 17
August 2011.
Retrieved 27 July 2014...
- €3 to €9 per tablet,
typically containing 25–65 mg of MDMA. By 2014 the
EMCDDA reported that the
range was more
usually between €5 and €10 per tablet,...
- drug profile".
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA).
January 8, 2015.
Zevzikovas A,
Kiliuviene G,
Ivanauskas L,
Dirse V (2002)...
- α-PiHP was
first identified as a
designer drug when it was
reported to the
EMCDDA by a
forensic laboratory in Slovenia. It is a
positional isomer of pyrovalerone...
- been sold as a
designer drug,
first being definitively identified by the
EMCDDA in
Sweden in 2016. It is the
bromo instead of
chloro analogue of alprazolam...
-
Decision 2005/387/JHA)".
EMCDDA. July 2014.
Retrieved 8
August 2014.
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA) (2021). "Synthetic cannabinoids...
-
reported to the
European Monitoring-Center for
Drugs and Drug
Addiction (
EMCDDA).
Reported user
negative effects include palpitations, paranoia, intense...
